3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
2
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Genitourinary
4
Conditions
Urinary Bladder Neoplasms
15
Carcinoma, Transitional Cell
15
Urologic Neoplasms
4
Ureteral Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
3
Urethral Neoplasms
2
Metastatic Urothelial Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Peripheral Nervous System Diseases
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Muscle-invasive Bladder Cancer
1
Metastatic Urothelial Cancer and Other Malignant Solid Tumors
1
Male Urogenital Diseases
1
Head and Neck Neoplasms
1
Female Urogenital Diseases
1
Esophageal Neoplasms
1
Carcinoma in Situ
1
Advanced Solid Tumor
1
Interventions
Gemcitabine
7
Cisplatin
5
pembrolizumab
4
enfortumab vedotin
4
Mitomycin
4
Trastuzumab
3
Pemetrexed
3
Carboplatin
3
dodecyl maltoside
2
atezolizumab
2
Sunitinib
2
vinflunine
1
valrubicin
1
tucatinib
1
palbociclib
1
niraparib
1
motexafin gadolinium
1
cabozantinib
1
avelumab
1
apatorsen
1
Water
1
VMBP protocol
1
Standard of Care
1
Radiation Dose Hypofractionation
1
Nivolumab
1
Neoadjuvant Therapy
1
Immunoglobulins, Intravenous
1
Gels
1
GSK-3326595
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
INDUSTRY
×
Urologic Neoplasms
×
enfortumab vedotin
×
Clear all
NCT05614739
2026-05-19
FORAGER-1
Eli Lilly and Company
Phase 1
Recruiting
535 enrolled
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA
NCT03219333
2024-08-27
EV-201
Astellas Pharma Inc
Phase 2
Completed
219 enrolled
32 charts
2 FDA